Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

导出 OA

翻译打印收藏纠错

第一作者： Mehra,Golshan

第一单位： Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. mgolshan@partners.org.

作者： Mehra,Golshan ^[1] ; Constance T,Cirrincione ^[2] ; William M,Sikov ^[3] ; Lisa A,Carey ^[4] ; Donald A,Berry ^[5] ; Beth,Overmoyer ^[6] ; Nora L,Henry ^[7] ; George,Somlo ^[8] ; Elisa,Port ^[9] ; Harold J,Burstein ^[6] ; Clifford,Hudis ^[10] ; Eric,Winer ^[6] ; David W,Ollila ^[11] ; Alliance for Clinical Trials in Oncology

作者单位： Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. mgolshan@partners.org. ^[1] Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA. ^[2] Program in Women's Oncology, Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, Providence, RI, USA. ^[3] Department of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ^[4] Alliance Statistics and Data Center, M D Anderson Cancer Center, Houston, TX, USA. ^[5] Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. ^[6] Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA. ^[7] Department of Medical Oncology, City of Hope Medical Center, Los Angeles, CA, USA. ^[8] Department of Surgery, Mount Sinai School of Medicine, New York, NY, USA. ^[9] Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. ^[10] Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ^[11]

关键词 Breast conserving therapy HER2-positive breast cancer Neoadjuvant therapy